knowledge -WSS

knowledge

author：hotspot 2025-09-28 17:06:52 - browse：2

empty test tubes in the hand. -- first opinion coverage from STAT — Adobe

The Food and Drug Administration on Friday announced its intention to start regulating tests developed in laboratories — closing the “Theranos loophole” that has allowed inaccurate tests to slip through the cracks.

Lawmakers came close last year to passing a bill that would have given the FDA this authority, but it was ultimately rejected by Republicans who sympathized with the labs in academic medical centers and hospitals that opposed the provision. FDA Commissioner Robert Califf said at the time that if the bill failed, the agency would take matters into its own hands.

The proposed rule fulfills that promise, adding lab diagnostics to the list of devices that fall under FDA enforcement — a move that patient groups and non-lab test makers support, and that laboratories are likely to dispute. When the FDA started regulating medical devices in 1976, lab-developed tests were simple and offered mostly to local patient populations. The agency generally allowed labs to use these tests without submitting proof of their efficacy.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Readers discuss the intersection of pregnancy and addiction

WSS

Lawmakers grill UnitedHealth CEO on Change cyberattack

Deposition: Sackler embraced plan to conceal OxyContin’s strength

Statins may not be needed by millions of people, study suggests

Primary care doctor shortage won't be solved by free med school tuition

How faith leaders like me can help address America's obesity epidemic

PBM executives asked to testify by House panel

hotspot

knowledge

knowledge

Hepatitis C has a cure — but many Americans still lack access to it

Is it ever OK for doctors to lie to their patients?

Novavax promises a turnaround & Lilly roils the obesity market

Chemotherapy before breast cancer surgery might fuel metastasis

Affirmative action in medical school literally saved lives

FDA reviewers ask if approval of Lilly’s Alzheimer’s drug should be restricted

The cancer drug shortage isn’t new — and neither are the solutions

Cancer thrives by mutating. But sometimes, a mutation leaves it vulnerable

What does generative AI mean for health care? We asked experts

Primary care doctor shortage won't be solved by free med school tuition

hotspot

Lilly's Alzheimer's drug donanemab backed by FDA advisers

HHS's proposed rule does nothing to address the climate crisis

5 takeaways from STAT's examination of Zynex Medical

Lilly's Alzheimer's drug donanemab backed by FDA advisers

GSK’s asthma push continues as drug succeeds in Phase 3 trials

AltruBio raises $225 million to develop ulcerative colitis drug

Wikipedia

entertainment

knowledge

explore